Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer

ConclusionFruquintinib emerges as a promising therapeutic option for refractory mCRC. However, its cost-effectiveness depends on selected willingness-to-pay (WTP) threshold. While the drug ’s ICER surpasses the WTP based on China's 2022 GDP per capita, it remains below the threshold set at three times the national GDP.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research